AOD-9604 in Itápolis — Fat Loss Peptide Research Guide
AOD-9604 research guide for Itápolis. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 isn't found on pharmacy shelves in Itápolis or most other cities — this is a specialist compound distributed through a dedicated online market. What this means for Itápolis researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those evaluation tools are available to every researcher. Vendors worth sourcing from proactively publish batch-matched Certificates of Analysis showing HPLC purity data, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. The sections below cover what Itápolis researchers need to know about purchasing, testing, and working with AOD-9604 for research purposes.
How AOD-9604 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Itápolis comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Where to Buy AOD-9604 — A Researcher's Guide
Quality AOD-9604 sourcing begins with a simple filter: does this vendor publish batch-specific COAs proactively? Suppliers that publish proactively are operating transparently. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from microbial contamination can trigger severe inflammatory responses even at trace quantities. Signs of a credible vendor beyond COA quality: documented vendor history spanning multiple years, responsive technical support who understand testing methodology, and cold chain packaging that protects product integrity. For Itápolis researchers making a first AOD-9604 purchase: apply these quality criteria before ordering, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order AOD-9604 — ships to Itápolis
COA-verified · International tracking · Research grade
AOD-9604 is sold for research purposes only and is not approved for human consumption by the FDA or equivalent regulatory bodies — all information here is for educational purposes only. Reconstitute AOD-9604 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — equivalent to 25mcg per unit on an insulin syringe. The most significant preventable safety hazard in AOD-9604 research is endotoxin from inadequately tested product — a confirmed endotoxin test result in the lot-matched COA is the direct mitigation for this hazard. Researchers using AOD-9604 alongside other research compounds should review the available literature for documented interactions before running stacked compound experiments.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
